Veozah and Progesterone HRT: What You Need to Know About This Interaction

The Short Answer: Yes, You Can Usually Take These Together, With Caveats

Most women in perimenopause or post-menopause who need both hot flash control and progesterone for uterine protection can use fezolinetant and progesterone together. The FDA label for fezolinetant does not list progesterone as a contraindicated combination. The concern is additive sedation, not a dangerous metabolic clash. Timing your progesterone dose at bedtime, where it is already standard practice, goes a long way toward minimizing any daytime drowsiness.

Every woman's situation is different. If you have a history of falls, take other sedating medications, or are starting both drugs at the same time, your clinician needs the full picture before you proceed.

Why This Question Comes Up: The Two Drugs and Why Women Need Both

What Fezolinetant (Veozah) Does

Fezolinetant is a selective neurokinin 3 (NK3) receptor antagonist approved by the FDA in May 2023 for moderate-to-severe vasomotor symptoms (VMS) in menopause. It is the first non-hormonal, non-SSRI/SNRI prescription option specifically designed for hot flashes and night sweats.

The mechanism targets the thermoregulatory circuit in the hypothalamus. During menopause, falling estrogen levels cause KNDy neurons (named for kisspeptin, neurokinin B, and dynorphin) to over-fire, sending exaggerated heat-dissipation signals that produce hot flashes. Fezolinetant blocks neurokinin B from binding to NK3 receptors on these neurons, quieting the misfiring. The SKYLIGHT 1 and SKYLIGHT 2 trials showed that 45 mg daily reduced the frequency of moderate-to-severe hot flashes by approximately 60% compared with baseline at 12 weeks, significantly outperforming placebo.

The drug does not contain estrogen or progestogen. It does not stimulate the endometrium. Women who cannot or prefer not to use hormone therapy are the primary audience.

Why Some Women Also Take Progesterone

Progesterone HRT is prescribed to protect the uterine lining in women who still have a uterus and are using estrogen. Without it, unopposed estrogen raises the risk of endometrial hyperplasia and carcinoma. The Menopause Society's 2023 position statement reinforces that any woman with an intact uterus who uses systemic estrogen must also use an adequate progestogen.

Oral micronized progesterone (brand name Prometrium in the US) is the most commonly prescribed form in the US. The standard doses are 100 mg nightly for continuous combined regimens and 200 mg nightly for 12 days per cycle in sequential regimens. Progesterone is also available as a vaginal insert and an intrauterine device (Mirena, Liletta), which produce negligible systemic absorption and no sedation.

But here is where the practical question arises: some women in perimenopause or post-menopause are already on progesterone for uterine protection alongside estrogen, and they still have breakthrough hot flashes. Adding fezolinetant is a legitimate clinical strategy in that scenario.

The Pharmacology of the Interaction: CYP Enzymes, P-gp, and PD Effects

Fezolinetant's Metabolic Profile

Fezolinetant is metabolized primarily by CYP1A2. This is the most clinically significant piece of its interaction profile. Strong CYP1A2 inhibitors such as fluvoxamine and ciprofloxacin are contraindicated with fezolinetant because they can push systemic exposure to fezolinetant up by more than 10-fold. Moderate CYP1A2 inhibitors such as mexiletine are also flagged in the label.

Progesterone is not a meaningful CYP1A2 inhibitor or inducer at clinical doses. So the metabolic pathway of fezolinetant is not affected by progesterone.

Fezolinetant is also a substrate and inhibitor of MATE1 and MATE2-K transporters, but progesterone does not interact with these either at the doses used in HRT.

Progesterone's Metabolic Profile

Oral micronized progesterone undergoes extensive first-pass metabolism in the gut and liver. Its primary metabolites include 5-alpha-dihydroprogesterone and allopregnanolone. Allopregnanolone is a potent positive allosteric modulator of GABA-A receptors, which is the direct source of its sedating effect. This is not a CYP-mediated interaction with fezolinetant. It is a downstream pharmacodynamic one.

Progesterone is metabolized largely by CYP3A4. Fezolinetant does not inhibit or induce CYP3A4 in a clinically meaningful way at its therapeutic dose of 45 mg, so progesterone levels are not expected to change when fezolinetant is added.

The Actual Interaction: Additive CNS Depression

The interaction between fezolinetant and progesterone is pharmacodynamic (PD), not pharmacokinetic (PK). That means it is not about one drug changing the blood level of the other. It is about both drugs producing overlapping central nervous system effects.

Fezolinetant's CNS effects are relatively modest. In the SKYLIGHT 1 trial, insomnia was actually listed as a reported adverse event in a small percentage of participants, and somnolence was not flagged as a major concern at 45 mg. But any centrally acting drug adds some CNS burden.

Oral progesterone's sedative effect is well-documented and dose-dependent. One randomized controlled trial by Caufriez et al. demonstrated that oral progesterone 300 mg significantly increased slow-wave sleep and reduced wakefulness compared with placebo in post-menopausal women. At the 100-200 mg doses used in HRT, the sedation is real but typically mild and transient, which is why evening dosing is the clinical standard.

When both agents are present, the sedation signals may add together rather than cancel. This is the definition of a minor-to-moderate pharmacodynamic additive interaction per standard DDI classification frameworks.

Severity Classification and What Clinical DDI Databases Say

No head-to-head controlled study has examined fezolinetant plus oral progesterone as a specific combination in a randomized trial. The evidence here is extrapolated from the known pharmacology of each drug and from the broader literature on oral micronized progesterone's CNS effects. Standard interaction databases such as Lexicomp and Micromedex classify this combination as a minor interaction, citing additive sedation as the mechanism. The FDA label for fezolinetant does not list progesterone among contraindicated or major interaction drugs.

The WomanRx clinical team has reviewed prescribing patterns among women on combined estrogen-progesterone HRT who were enrolled in the SKYLIGHT trials. The SKYLIGHT 4 open-label safety extension of 52 weeks included women using concomitant hormonal therapies, and the adverse event profile was consistent with the shorter trials. This does not constitute a formal subgroup analysis, but it suggests the combination is used in practice without alarming safety signals.

The key gradient here is between oral progesterone (significant sedation potential) versus vaginal or intrauterine progesterone (negligible systemic absorption, effectively no sedation). If the progesterone is delivered vaginally or via IUD, the PD interaction with fezolinetant becomes clinically irrelevant.

Who This Combination Is Right For, and Who Should Be Cautious

Women Who Are Likely Good Candidates

You may be a reasonable candidate for fezolinetant plus oral progesterone if:

• You have a uterus and are on systemic estrogen that requires progesterone for endometrial protection.
• You still experience moderate-to-severe hot flashes despite estrogen therapy.
• You take your progesterone at night and have no next-morning hangover effect.
• You have no history of falls, no other sedating medications, and no liver disease.
• You are in post-menopause and your symptom profile justifies adding a non-hormonal NK3 antagonist.

Women Who Should Be More Cautious or Consider Alternatives

You need a closer conversation with your clinician if:

• You are over 65 and at elevated fall risk. Daytime sedation from residual progesterone metabolites combined with any CNS effect of fezolinetant could increase fall risk. The American Geriatrics Society Beers Criteria lists oral progesterone as a medication to use with caution in older adults due to CNS effects, and that caution compounds when additional centrally active drugs are added.
• You take other sedating drugs: gabapentin, antihistamines, benzodiazepines, z-drugs, certain antidepressants. The additive burden rises with each agent.
• You are in perimenopause and still cycling. Fezolinetant is approved for VMS in menopause broadly, but the interaction with fluctuating endogenous progesterone levels in perimenopause adds physiological complexity that is not yet well-studied.
• You have hepatic impairment. Fezolinetant is contraindicated in moderate or severe hepatic impairment per the FDA label, and oral progesterone metabolism is also hepatic.
• You have known liver enzyme elevations. SKYLIGHT 4 identified a small percentage of participants with alanine aminotransferase (ALT) elevations exceeding three times the upper limit of normal, which prompted the label to include a liver function monitoring recommendation.

Pregnancy, Lactation, and Contraception: Required Reading

Fezolinetant in Pregnancy

Fezolinetant is contraindicated in pregnancy. The FDA label carries no formal letter category under the 2015 labeling framework, but the label states plainly that fezolinetant should not be used during pregnancy. Animal reproductive toxicity data showed adverse developmental outcomes, and there are no adequate human data in pregnant women.

Neurokinin B signaling plays a role in placentation and fetal development. Blocking NK3 receptors during pregnancy is a theoretical concern beyond just the absence of safety data. Until human evidence proves otherwise, fezolinetant must be avoided in any woman who is pregnant or planning pregnancy.

If you are in perimenopause and still have ovulatory cycles, even infrequent ones, fezolinetant does not provide contraception. You need reliable contraception if pregnancy is possible. ACOG guidance on contraception in perimenopause notes that ovulation can occur unpredictably during perimenopause even when cycles are irregular, and women should not assume menopause until 12 months of amenorrhea.

Fezolinetant in Lactation

No data exist on fezolinetant transfer into human breast milk. Animal data show the drug and its metabolites are present in milk. The label recommends against use during breastfeeding. In practice, fezolinetant's primary indication is menopause-related VMS, making postpartum or lactating use uncommon. But if a postpartum woman has vasomotor symptoms (which can occur due to postpartum estrogen withdrawal), fezolinetant is not the appropriate choice while she is breastfeeding.

Progesterone HRT in Pregnancy and Lactation

This article covers progesterone as HRT for uterine protection in menopausal and perimenopausal women. This is distinct from progesterone supplementation used in luteal phase support or early pregnancy preservation, which is a separate clinical indication.

For the HRT use case: women who are post-menopausal are not pregnant. Women in perimenopause who are on systemic HRT should be counseled that HRT does not reliably suppress ovulation in perimenopausal women with residual follicular activity, so effective contraception remains relevant.

Progesterone is present in human breast milk at low levels. The clinical significance for a breastfed infant is considered low, but the indication for progesterone HRT in a lactating woman would be unusual enough to warrant specialist input.

Monitoring, Timing, and Practical Guidance

Timing Is Your Primary Tool

The most practical way to minimize additive sedation is to take oral progesterone at bedtime. This is already the standard of care for oral micronized progesterone. The peak sedating effect of allopregnanolone metabolites aligns with sleep onset, and by morning the sedative burden has largely cleared. If fezolinetant is taken in the morning, the pharmacokinetic overlap with peak progesterone metabolite concentrations is minimized.

Fezolinetant's prescribing information does not specify a time of day for dosing. Discussing morning dosing of fezolinetant with evening progesterone gives you the widest separation.

Liver Function Monitoring

The FDA label recommends checking liver function tests before starting fezolinetant. If transaminases rise to more than three times the upper limit of normal, fezolinetant should be discontinued. This monitoring applies regardless of whether you are taking progesterone, but women on combined HRT who add fezolinetant should have baseline hepatic function documented before starting.

What to Watch For in the First Month

• Unusual daytime drowsiness or difficulty concentrating.
• Dizziness when standing, especially in the morning.
• Any change in fall frequency or near-miss events.
• Sleep quality changes. Fezolinetant can improve sleep disrupted by night sweats; progesterone may independently improve sleep architecture. The net effect for many women is actually positive.

When to Call Your Clinician Sooner

Contact your provider if you notice yellowing of skin or eyes, dark urine, or right upper quadrant pain. These could signal hepatotoxicity from fezolinetant, which though rare has been observed in post-marketing data.

How This Combination Fits Into the Broader Menopause Treatment Picture

The Menopause Society 2023 position statement acknowledges that non-hormonal therapies for VMS have an important place for women who cannot or choose not to use hormone therapy. Fezolinetant is specifically called out as a newly approved non-hormonal option. For women already on estrogen-progesterone HRT with breakthrough hot flashes, the statement supports individualized decisions about adding or switching non-hormonal agents.

A network meta-analysis published in Menopause in 2023 compared pharmacological treatments for VMS and found fezolinetant 45 mg among the more effective options for frequency reduction, comparable to moderate-dose systemic estrogen. This gives clinicians and patients real data to weigh when deciding whether adding fezolinetant to an existing HRT regimen makes sense.

The broader drug interaction list for fezolinetant includes strong and moderate CYP1A2 inhibitors (contraindicated or use with caution), and these are more clinically pressing than the progesterone interaction. Drugs in that category include fluvoxamine, ciprofloxacin, and mexiletine. If you are on any of these, that conversation needs to happen before fezolinetant even enters the picture.

Smoking induces CYP1A2 and can reduce fezolinetant plasma concentrations. Women who smoke may see reduced efficacy, though the label does not set a dose adjustment for this. This is worth noting because smoking status changes the entire risk-benefit equation in menopausal women, given cardiovascular and bone-density implications.

A Note on the Evidence Gap

Women have been historically underrepresented in drug-drug interaction studies, and menopausal women are especially poorly represented in formal DDI trials. The data informing the fezolinetant-progesterone combination is extrapolated from single-drug pharmacology, not from a controlled study pairing the two in perimenopausal or post-menopausal women.

As WomanRx reviewer Dr. Elena Vasquez, MD (OB-GYN and menopause specialist), notes: "The honest answer is that we are working from mechanism-based reasoning here, not a head-to-head trial of fezolinetant plus progesterone. That is the current state of the science for most non-hormonal menopause therapies. It does not make the combination unsafe, but it does mean patients and clinicians should pay attention to individual responses rather than assuming the absence of a contraindication means the absence of any interaction."

This kind of transparency matters. When your prescriber says the interaction is minor, they are working from the best available pharmacological evidence. They are not saying the combination has been studied in 2,000 post-menopausal women on Prometrium. It has not.

Quick Reference: Fezolinetant Drug Interaction Summary for Women on HRT

| Drug or Drug Class | Interaction Type | Severity | Clinical Action | |-|-|-|-| | Strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) | PK: elevated fezolinetant levels | Contraindicated | Do not combine | | Moderate CYP1A2 inhibitors (mexiletine) | PK: elevated fezolinetant levels | Use with caution | Monitor; consider alternatives | | Oral micronized progesterone | PD: additive CNS sedation | Minor to moderate | Time progesterone at night; monitor drowsiness | | Vaginal/IUD progesterone | Negligible systemic absorption | No meaningful interaction | No adjustment needed | | Estradiol (oral, patch, gel, spray) | Minimal PK interaction | Minor | No adjustment needed | | Gabapentin, z-drugs, benzodiazepines | PD: additive CNS sedation | Moderate | Discuss with prescriber; monitor closely |